Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Adding entacapone to levodopa may reduce dyskinesia in Parkinson's

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7195 p557-561
27 April 2002

This article
Reprint
Photocopy


News summary

Related websites
American Academy of Neurology (www.aan.com)


Adding entacapone to levodopa may reduce dyskinesia in Parkinson's

Entacapone used in combination with levodopa may be an effective early treatment for Parkinson's disease, say researchers from King's College London.

Professor Peter Jenner, director of the neurodegenerative diseases research centre, and colleagues compared the antiparkinsonian activity of levodopa with levodopa plus entacapone using a primate model of Parkinson's disease. They found that co-administration enhanced symptom control and reduced the occurence and severity of dyskinesias.

"By providing a more continuous stimulation of striatal dopamine receptors, the combination of levodopa and entacapone has the potential to avoid the development of dyskinesias. This supports the notion that levodopa continuous dopaminergic stimulation is important for preventing the priming effect that underlies involuntary movements in Parkinson's disease," Professor Jenner said.

Data from the study, which was supported by Novartis, were presented at the American Academy of Neurology congress in Denver, Colorado last week.

Entacapone (Comtess) is a COMT (catechol-o-methyltransferase) enzyme inhibitor. It is licensed as an adjunct to co-beneldopa or co-careldopa for patients with Parkinson's disease who experience end-of-dose deterioration and who cannot be stabilised on these combination therapies.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20006608

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.